To quantitatively analyze the total radioactivity in the excreta of healthy male subjects
after oral administration of [14C] SPH3127, and determine the cumulative excretion rate and
main excretion routes of radioactive substances; to investigate the partition in whole blood
and plasma and the pharmacokinetics of total radioactivity in plasma after a single oral
administration of [14C]SPH3127 in healthy male subjects; to identify the main metabolites in
healthy male subjects after an oral administration of [14C] SPH3127, determine the main
biotransformation pathways and main metabolites, quantitatively analyze the concentration of
SPH3127 and main metabolites in plasma by validated LC-MS/MS method, and establish the
pharmacokinetic parameters of SPH3127 and its main metabolites in plasma.